Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authori...
December 22 2020 - 9:07PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced that it will
convene its 2020 Annual Meeting of Stockholders on December 23,
2020 at 11:00 a.m. Eastern time and, after conducting all other
business, intends to adjourn the meeting solely with respect to
Item 2 set forth in its Definitive Proxy Statement filed with the
Securities and Exchange Commission on October 30, 2020. Item 2 is a
proposal to amend the Company’s Sixth Amended and Restated
Certificate of Incorporation to increase the number of authorized
shares of common stock. The Company is planning this adjournment to
provide its stockholders additional time to vote on Item 2. The
Annual Meeting will resume with respect to Item 2 at 11:00 a.m.
Eastern time on January 13, 2021 and will continue to be held
virtually.
Additionally, prior to the resumption of the Annual Meeting,
Ocugen intends to amend its Definitive Proxy Statement to restate
Item 2. The proxy amendment will modify the proposed amendment of
the Company’s Sixth Amended and Restated Certificate of
Organization by decreasing the proposed aggregate number of shares
of common stock that the Company would be authorized to issue from
500,000,000 shares to 400,000,000 shares. The proxy amendment
will be disseminated to stockholders of the Company as of the
record date on or about December 23, 2020.
The record date for determining stockholders eligible to vote at
the annual meeting will remain the close of business on October 28,
2020. Stockholders who have already submitted a proxy do not need
to vote again for the reconvened Annual Meeting, as the proxies
submitted will remain valid. Stockholders who have already
submitted proxies and want to change their vote with respect to
Item 2, as amended, can update their vote in the manner set forth
in the Definitive Proxy Statement. Your vote will be recorded at
the Annual Meeting in accordance with your most recently submitted
proxy.
Ocugen stockholders as of close of business on the
October 28, 2020 record date who have not voted are encouraged to
vote online at www.proxyvote.com
or by telephone at 1-800-690-6903. Stockholders that need
assistance voting or have questions, may contact Ocugen’s proxy
solicitation firm, Okapi Partners, at
info@okapipartners.com or (855)
208-8902.
Voting on Items 1, 3, 4, 5 and 6 will be open until the
adjournment of Ocugen's 2020 Annual Meeting of Stockholders
on December 23, 2020. Voting on Item 2 will be open
until the conclusion of the Annual Meeting on January 13, 2021. If
you hold your shares of our common stock with a broker, bank or
other holder of record as nominee or agent, you may be subject to
an earlier voting deadline and you should carefully review any
materials received from the nominee or agent regarding how to vote
your shares.
A copy of the Definitive Proxy Statement is available to
stockholders on the Company’s website and at the website maintained
by the SEC at https://www.sec.gov. A copy of the proxy
amendment will be available on those websites when filed by the
Company.
Ocugen stockholders as of the October 28, 2020 record date
for the Annual Meeting are invited to attend the virtual Annual
Meeting by
visiting www.virtualshareholdermeeting.com/OCGN2020.
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the SEC, including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact: LaVoieHealthScience Lisa
DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024